Allogene Therapeutics, Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Numerator: | |||||||||||
| Net loss | $ | (257,590) | $ | (327,265) | |||||||
| Denominator: | |||||||||||
| Weighted average common shares outstanding | 194,811,756 | 156,931,778 | |||||||||
| Net loss per share, basic and diluted | $ | (1.32) | $ | (2.09) | |||||||
| Year Ended December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Stock options to purchase common stock | 24,184,884 | 21,812,946 | |||||||||
| Restricted stock units subject to vesting | 13,343,793 | 12,180,471 | |||||||||
| Expected shares purchased under Employee Stock Purchase Plan | 1,913,748 | 2,168,264 | |||||||||
| Early exercised stock options subject to future vesting | — | 29,180 | |||||||||
| Total | 39,442,425 | 36,190,861 | |||||||||
Want the next Allogene Therapeutics, Inc. earnings per share disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Allogene Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 13, 2025 | Showing above |
| 2020 | Feb 25, 2021 | |
| 2019 | Feb 27, 2020 | |
| 2018 | Mar 8, 2019 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.